The FDA has granted accelerated approval to a new Alzheimer’s treatment, called Leqembi, the first drug of its kind with clear evidence it can slow cognitive decline in people with early stages of the disease.
“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” said Dr. Billy Dunn, director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, in a statement. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”
This is a developing story. Please check back for updates.